DMAAR
Drugs Made In America Acquisition Corp. RightsFinancial Services · $282M market cap
Verdict
We can't put a fair value on DMAAR right now. The financial data we receive for it contains an obvious error (its equity or assets jump more than 100× in one year). We'll value it once the data is corrected.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow DMAAR
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold DMAAR. In Q2 2026, 1 trimmed. Who we track
Howard Marks
Oaktree Capital Management · as of Q2 2026
$13.5B
14,041,000 shares
Howard Marks
Oaktree Capital Management · as of Q2 2026
$396.0M
399,999 shares
Moves in Q2 2026
Trimmed: Howard Marks
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate…
Shell Companies
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works